LTP
LTR PHARMA FPO [LTP]
Healthcare · ASX Small Cap
$0.4100 +0.0%
Updated 26 Mar 2026 · Scores refresh every scan
Appeared in 2 consecutive scans→ Score +10First seen: 2026-02-25
Score Breakdown
Technical53
Catalyst51
Sentiment50
Fundamental50
Momentum50
Risk Gate46
Get alerts when LTP's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Active Signals
Bullish Signals
- RSI drifting toward oversold territory — worth watching
- Strong cash runway (15 quarters)
- Very high P/S ratio (65.9x)
- Revenue in sharp decline (-84%)
- Small-cap ($20-100M)
- Sentiment is mixed — no strong consensus either way
- Positive long-term momentum — up 34% over the past year
- Altman Z-Score grey zone (1.92, low-confidence approx)
- RBA hiking (-3pts)
Risk Signals
- Trading below both moving averages — the trend is working against this one
- Below the 200-day average — the long-term trend is still working against it
- Piotroski F-Score weak (3/9, low-confidence approx)
- Not enough chatter to gauge sentiment — defaulting to neutral
- Revenue declining at -84% — the top line is shrinking
- The bigger volume days are the down days — volume-weighted momentum is negative (-1.33%/day)
- Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about LTP
3 free messages/day · Unlimited with Pro
Recent Catalysts
LOW Investor Presentation
MEDIUM SPONTAN Phase II Clinical Study Completes Recruitment
NONE Appendix 4D and Half Yearly Report
NONE Application for quotation of securities - LTP
NONE SPONTAN Shows Positive Outcomes in Younger Men with ED
Recent ASX Announcements
| 2026-03-10 | Investor Presentation |
| 2026-03-04 | SPONTAN Phase II Clinical Study Completes Recruitment PRICE SENSITIVE |
| 2026-02-25 | Appendix 4D and Half Yearly Report PRICE SENSITIVE |
| 2026-02-10 | Application for quotation of securities - LTP |
| 2026-02-01 | SPONTAN Shows Positive Outcomes in Younger Men with ED PRICE SENSITIVE |
Key Metrics
$74.5M
Market Cap
163K
Avg Volume
1.1x
Vol Ratio
$0.27 — $0.81
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-29.3%
ROE
N/A
Profit Margin
CANSLIM Analysis
| Factor | Rating | Detail | |
|---|---|---|---|
| C | Current EPS | fail | EPS Growth: 0% |
| A | Annual Earnings | fail | CAGR: 0% |
| N | New Highs / Catalysts | neutral | |
| S | Supply & Demand | neutral | Float: 59% |
| L | Leader vs Laggard | laggard | RS: -10 |
| I | Institutional Sponsorship | insufficient_data | Inst: 0% |
| M | Market Direction | neutral | Neutral |
Sector: Healthcare
Ranked #71 of 117 · Sector avg: 46
View all Healthcare signals →Track LTP and 2,200+ ASX stocks
Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.
No credit card required